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Sphingolipid activator proteinhe lysosomal compartment by endocytosis, phagocytosis, or autophagy. Within
the lysosomal compartment, membrane components of complex structure are degraded into their building
blocks. These are able to leave the lysosome and can then be utilized for the resynthesis of complex
molecules or can be further degraded. Constitutive degradation of membranes occurs on the surface of intra-
endosomal and intra-lysosomal membrane structures. Many integral membrane proteins are sorted to the
inner membranes of endosomes and lysosome after ubiquitinylation. In the lysosome, proteins are degraded
by proteolytic enzymes, the cathepsins. Phospholipids originating from lipoproteins or cellular membranes
are degraded by phospholipases. Water-soluble glycosidases sequentially cleave off the terminal
carbohydrate residues of glycoproteins, glycosaminoglycans, and glycosphingolipids. For glycosphingolipids
with short oligosaccharide chains, the additional presence of membrane-active lysosomal lipid-binding
proteins is required. The presence of lipid-binding proteins overcomes the phase problem of water soluble
enzymes and lipid substrates by transferring the substrate to the degrading enzyme or by solubilizing the
internal membranes. The lipid composition of intra-lysosomal vesicles differs from that of the plasma
membrane. To allow at least glycosphingolipid degradation by hydrolases and activator proteins, the
cholesterol content of these intraorganellar membranes decreases during endocytosis and the concentration
of bis(monoacylglycero)phosphate, a stimulator of sphingolipid degradation, increases. A considerable part
of our current knowledge about mechanism and biochemistry of lysosomal lipid degradation is derived from
a class of human diseases, the sphingolipidoses, which are caused by inherited defects within sphingolipid
and glycosphingolipid catabolism.
© 2008 Elsevier B.V. All rights reserved.1. Lysosomal membrane digestionLysosomes are major degradative compartments of eukaryotic
cells. In contrast to the proteasome, lysosomes degrade a wide variety
of structurally diverse substances, such as proteins, glycosaminogly-
cans, nucleic acids, oligosaccharides, and complex lipids, into their
building blocks [1]. These can leave the lysosomes either via diffusion,
or with the aid of specialized transporters [2]. In the cytosol, the
building blocks can be further degraded to fuel energy metabolism or
can re-enter biosynthetic pathways. To provide building blocks of
complex macromolecules for salvage and recycling pathways seems to
be an important function of lysosomes. It has been shown, that in note; CADs, cationic amphiphilic
1,4Glcβ1ceramide; GM2, Gal-
GM2 activator protein; GSL,
oteins; MVBs, multivesicular
golipid activator proteins (Sap
49 228 737778.
.
ll rights reserved.very rapidly dividing cells, glycosphingolipids (GSL) are synthesized
predominantly from sphingoid bases, carbohydrates and sialic acids
released by lysosomes. In human foreskin ﬁbroblasts for example, 90%
of the glucosylceramide derives from recycling of sphingoid base, only
10% is synthesized de novo [3]. Under this aspect, the concept of
lysosomes as waste dumps within cells would be a misleading
association and should be replaced by the idea of lysosomes as
stomachs of the cell, that provide macromolecule constituents and
ensure lipid homeostasis.
1.1. Endocytosis and autophagy
Eukaryotic cells maintain highly regulated transport systems that
convey cargo into the cell or exchange membranes and cargo between
cellular organelles. Cellular and foreign cargo, but alsomembranes can
reach the endosomal–lysosomal systemvia endocytosis, phagocytosis,
autophagy, or direct transport. The various cellular functions
associated with this process require degradation steps within the
lysosomes, where proteins, complex cargo constituents, or complex
membrane lipids have to be cleaved. During endocytosis, cargo enters
the cell via clathrin-dependent or -independent mechanisms in a
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membranewith and without receptor proteins are internalized, trafﬁc
through the endosomal compartment, and undergo different steps of
sorting, before they are either recycled to the plasma membrane, or
delivered to the lysosome for degradation. They reach the lysosome
either as intra-lysosomal membrane structures or as part of the
perimeter membrane [5,6]. During endosomal maturation, the
luminal pH value decreases from values of about 7.2 to below 5 [7].
The endosomal membrane consists of different domain arrange-
ments, in which Rab proteins are localized in morphologically
distinct domains, like in a mosaic. Endosomes comprised of different
domain arrangements display biochemical and possibly functional
diversity [8].
Cellular macromolecules can be degraded by different pathways in
eukaryotic cells. Ubiquitinylated proteins are degraded by the
proteasomal system in the cytosol, bulk cytoplasma and organelles
are delivered to the lysosome by (macro)autophagy [9] and cellular
membranes are degraded in the lysosome after endocytosis. Auto-
phagy requires a membrane degradation step, before cargo can be
degraded by the lysosomal degradation system. Autophagy represents
a unique form of membrane trafﬁcking, in which membrane
compartments (autophagosomes) engulf organelles or cytosolic
cargo and deliver them to the lysosome for degradation [10]. Under
normal growth conditions, autophagy occurs at a basal level.
Starvation dramatically induces autophagy to maintain a pool of
basic nutrients. Autophagy is evolutionary conserved in eukaryotes.
Insights into the molecular pathways of autophagy were mainly
gained by genetic approaches in yeast mutants defective in autophagy.
Degradation of autophagic bodies occurs in yeast in the vacuole.
Autophagy starts with the formation of autophagosomes, double-
membrane-layered vesicles, which enclose cytosol or organelles [11].
In yeast, after fusion with the vacuole, the autophagosome is released
into the lumen as a single-membrane vesicle and termed autophagic
body. The breakdown of this subvacuolar vesicle depends on the acidic
pH of the vacuole [12], and on vacuolar proteinase A and proteinase B
(Prb1) [13]. However, the function of Prb1 might be to activate
vacuolar zymogens that play a direct role in the breakdown process
[14]. Two other proteins have also been implicated in membrane
degradation, the putative lipases Aut5 [11] and Aut4 [15].
Another role of autophagy in membrane degradation is that it is a
source of bis(monoacylglycero)phosphate (BMP, erroneously also
called lysobisphosphatidic acid, Fig. 1). This negatively charged lipid is
highly enriched in the internal membranes of the lysosome and
required for degradation of small GSL [16]. Biosynthetically, BMP is
formed during the degradation of phosphatidylglycerol and cardioli-
pin, presumably on the surface of intra-lysosomal vesicles [17,18].
Cardiolipin in turn, reaches the lysosome as a component ofFig. 1. Structure of bis(monoacylglycero)phosphate (BMP).mitochondria by macroautophagy. Its degradation leads to formation
of BMP on internal membranes.
In eukaryotes, transmembrane proteins destined for lysosomal
degradation are in eukaryotes often monoubiquitinylated and sorted
in endosomal multivesicular bodies (MVBs) [19]. MVB formation
requires the sequential action of three endosomal sorting complexes
needed for transport (ESCRT-I,-II,-III) [20]. MVBs follow the pathway
from early to late endosomes, and are eventually delivered to
lysosomes, where they are degraded together with their protein
cargo [21].
1.2. Topology of degradation
In the endosomal–lysosomal system, a variety of hydrolytic
enzymes with acidic pH-optima cleave macromolecules such as
proteins, polysaccharides, nucleic acids, glycoconjugates, and phos-
pholipids. To protect the interior of the cell from these degradative
enzymes, the integrity of the limiting membrane has to be
preserved during the process of lysosomal degradation. This is
achieved by a thick glycocalyx [22] composed of the carbohydrate
part of lysosomal integral membrane proteins (LIMPS) and
lysosomal associated membrane proteins (LAMPS) [23]. The
enzymes required for lipid degradation cannot be expected to
reach their substrates through this glycocalyx, which is composed of
glycoproteins highly N-glycosylated with polylactosamine units.
Since the perimeter membrane is protected from degradation, a
second distinct pool of membranes has to be present in the
endosomal/lysosomal compartment. This has been proposed in
1992 [5] and has been conﬁrmed by independent groups. According
to our current view, former parts of the plasma membrane destined
for degradation reach the lysosome as part of small intra-lysosomal
vesicles, in which the former extracytoplasmic membrane leaﬂet
faces the lumen of the lysosome (Fig. 2). These intra-lysosomal
vesicles provide the platform of membrane degradation. As
indicated by studies with human patients with defects in GSL
degradation, the surface of the inner lysosomal membranes
represents the main site of membrane degradation in eukaryotic
cells. Intra-lysosomal membranes have been initially observed,
when different membrane degradation steps are defective. This
was the case in cells from patients with sphingolipid storage
diseases such as GM1 gangliosidosis [24] or combined sphingolipid
activator protein (Sap) deﬁciency [25], where they accumulate as
multivesicular storage bodies. Later on, they have been identiﬁed as
MVBs [21,26]. Complementing the media of Sap-precursor-deﬁcient
ﬁbroblasts with nanomolar concentrations of puriﬁed Sap-precursor
reversed the aberrant accumulation of multivesicular structures, and
restored the cells ability to degrade glycosphingolipids [27].
1.3. Lipid composition of lysosomal membranes
The lipid composition of limiting membrane and the intra-
lysosomal membrane structures differs considerably from each
other and from that of plasma membrane or the limiting membranes
of other cellular organelles. In addition, the luminal pH value steadily
decreases to achieve optimal conditions for the action of lysosomal
enzymes. Besides the lipid composition, also the protein composition
of the internal membranes is adjusted during endosomal sorting [28].
The intra-lysosomal membranes are formed by a lipid-sorting process
along the endocytic pathway, during which its cholesterol content
decreases and that of the negatively charged lipid BMP increases
[16,29]. Due to its unusual sn1,sn1′-conﬁguration, BMP has a
sufﬁciently long lifetime in spite of the presence of the lysosomal
phospholipases [30]. While intra-lysosomal membranes are enriched
in BMP, this lipid is almost absent in the perimeter membrane,
distinguishing the two membrane pools [16,29]. Other anionic lipids
like phosphatidylinositol and dolichol phosphate, albeit in smaller
Fig. 2. Model of endocytosis and lysosomal degradation of membranes (modiﬁed from [51]). Parts of the plasma membrane, including GSL, are endocytosed by coated pits or
caveolae. The GSL derived from the plasma membrane reach the lysosome in small intra-lysosomal vesicles facing the lysosomal lumen and are degraded there. The lysosomal
perimeter membrane is protected from digestion by a glycocalyx.
676 H. Schulze et al. / Biochimica et Biophysica Acta 1793 (2009) 674–683amounts than BMP, are also found within the lysosomal compartment
[31,32]. Membrane-stabilizing cholesterol is almost absent from intra-
lysosomal membranes [16,29].
Cellular membranes contain cholesterol in different concentra-
tions. Although it is incorporated into the membrane of the
endoplasmatic reticulum, cholesterol-concentrations are low, with
the consequence that transbilayer movements are facilitated. The
plasmamembrane is especially rich in cholesterol, more rigid, and has
a greater diameter. In the plasma membrane, cholesterol is tightly
associated with sphingomyelin. Although concentrations vary
between membranes, the fraction of “free” cholesterol might be
comparable. Its “activity” might be constant, but real cholesterol
concentrations are regulated by the “friends” (sphingomyelin) and
“enemies” (ceramide) of cholesterol in the endoplasmic reticulum
and the inner lysosomal membranes. Cholesterol concentration is a
crucial factor for the degradation of membranes. During the endocytic
pathway the luminal pH decreases and sphingomyelin is degraded by
acid sphingomyelinase, with a pH optimum of about 5.5, to ceramide.
It has been shown, that ceramide can selectively displace cholesterol
from ordered lipid domains [33]. Increasing ceramide content of the
internal membranes correlates with decreased cholesterol levels,
which make the membrane less rigid. Cholesterol, which cannot be
degraded in the lysosome, has to be transported out of the inner
membranes of the organelle. This is achieved by the NPC1/NPC2-
system. It can be assumed that the ceramide content of the
intraendosomal vesicles is the highest in the endosomal/lysosomal
pathway, since at an endosomal pH value of 5.5 ceramide is liberated
from sphingomyelin by the acid sphingomyelinase. At the pH value of
5.5 acid ceramidase, the enzyme hydrolyzing ceramide with a
lysosomal pH optimum, catalyzes the reverse reaction, the synthesis
of ceramide, keeping sphingosine levels within the endosome low[34]. Sphingosine would act as a cationic amphiphile and induce
lipidosis by neutralizing the negative charge of BMP and displace
lysosomal proteins from membranes.
The unique lipid composition, together with membrane curvature
and acidic environment appears to be required for degradation of
intra-lysosomal vesicles. In some cases, lysosomal lipid catabolism
requires the presence of lysosomal lipid binding proteins. These
membrane-active proteins bind lipids and transfer them to proteins
or to target membranes [35]. Lysosomal lipid binding proteins
comprise, among others, the sphingolipid activator proteins, the lipid
antigen presenting CD1 molecules, one of the oxysterol binding
protein-related proteins [36], and the cholesterol-binding proteins,
like NPC1, a transmembrane protein, and the soluble NPC2. Although
other lipids like sphingomyelin, the major storage substance in
Niemann–Pick Disease Types A and B, are also stored in Niemann–
Pick Type C (NPC), the disease is caused by impaired cholesterol exit
out of the late endosomes and lysosomes. This is due to mutations in
the genes encoding the NPC1 or NPC2 protein, and lead to a
neurodegenerative disease.
The membrane lipid cholesterol can reach the endosomes by
endocytic membrane ﬂow. Cholesterol and cholesteryl esters can
enter cells of different types by receptor-mediated endocytosis, and
as components of lipoproteins, such as low density lipoprotein or
high density lipoprotein (HDL). Lipoproteins are delivered to the late
endosome, where the cholesteryl esters are hydrolyzed, liberated
cholesterol is bound by NPC2 [37–39], and transferred to a
cholesterol binding site of NPC1 [40] for export out of the endosomal
system. The NPC1 protein is composed of 13 membrane-spanning
helices and three large loops that project into the lumen of
endosomes. The luminal loop-1, a 240-amino acid domain with 18
cysteines has been identiﬁed as cholesterol and oxysterol binding
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lipophilic molecules through the glycocalyx of lysosomal perimeter
membranes and presumably also out of the endosomal–lysosomal
system [41,42] (Fig. 3).
In ﬁbroblasts from NPC patients, exit of liberated cholesterol from
the late endosomes and lysosomes is attenuated and it accumulates in
the organelles. Secondarily, other membrane components also
accumulate. Storage of neutral glycolipids such as glucosylceramide
and lactosylceramide, acidic glycolipids, especially of gangliosides
GM3 and GM2, sphingomyelin (less than in Nieman–Pick disease,
Types A and B), BMP, and phospholipids occurs in liver, spleen, brain,
and other organs [43]. This can be easily explained by a kind of trafﬁc
jam, that occurs when lipids accumulate. Lipids of other structure and
hydrophobic proteins can dissolve in the accumulating membranes,
precipitate, and prevent further degradation.
1.4. Lysosomal degradation of proteins
Lysosomal proteolytic enzymes, the cathepsins, catalyze the
hydrolysis of proteins [44]. Few of the proteinases work as amino-
or carboxypeptidases, while most are endopeptidases. Most cathe-
psins belong to the aspartic, cysteine, or serine proteinase families of
hydrolytic enzymes. They are expressed in a tissue- or cell type-
speciﬁc manner and are usually detected within all vesicles of the
endocytic pathway. In speciﬁc cell types, they can also be secreted and
might fulﬁll tasks in the direct pericellular surrounding. Functions of
lysosomal proteases comprise bulk protein degradation within
lysosomes, antigen processing within early endosomes, proprotein
processing, prohormone processing, and degradation of matrix
constituents in the extracellular space. In addition, lysosomal
proteases have been proposed also to contribute to the initiation of
apoptotic processes within the cytosol [44]. In addition to their
enzymatic function, complexes of lysosomal proteins including the
cathepsins lead to enhanced lifetimes of other proteins in the
lysosomal environment, as in the case of cathepsin A, neuraminidase,
and β-galactosidase [45,46]. Also lipid-modiﬁed proteins are
degraded within the lysosomal compartment.
The lysosomal degradation of prenylated and palmitoylated
proteins requires two lysosomal enzymes, palmitoyl-protein thioes-
terase (PPT1) and prenylcysteine lyase (PCL) [47]. PCL is a
membrane-associated ﬂavin-containing lysosomal monooxygenase
that converts prenylcysteine to a prenyl aldehyde. PPT1 cleaves fatty
acids from cysteine residues in proteins during lysosomal protein
degradation. Deﬁciency in the enzyme causes a neurodegenerative
lysosomal storage disorder, a variant form of infantile neuronal
ceroid lipofuscinosis.Fig. 3. In the late endosome ceramide is liberated from sphingomyelin (SM) by the acid sph
glucosidase and displaces cholesterol (indicated in red) from the internal membranes. Choles
N-terminus of the NPC1 is indicated by a blue dot.1.5. Degradation of phospholipids
Glycerophospholipids can be cleaved at various positions by
different phospholipases. Lysosomal phospholipases play a critical
role in the degradation of cellular membranes. Several phospholi-
pases, among them isoenzymes of acid phospholipase A, are present
in the lysosome. Lysosomal phospholipase A2 was characterized and
shown to have substrate speciﬁcity for phosphatidylcholine and
phosphatidylethanolamine. It is ubiquitously expressed, but is most
highly expressed in alveolar macrophages [48,49]. An enzyme with
phospholipase A2 and transacylase activity is the 1-O-acylceramide
synthase, which catalyzes in the presence of ceramide the formation
of 1-O-acylceramide by transacylation of fatty acids from the sn-2
position of phosphatidylcholine or phosphatidylethanolamine. In the
absence of ceramide or other alcohols as acceptors, the enzyme acts as
a traditional phospholipase A2 [50].
1.6. Disturbance of endosomal trafﬁcking and lysosomal digestion
In addition to the presence of hydrolyzing enzymes, degradation of
intra-lysosomal membranes requires a low pH value, high BMP
content, and low cholesterol levels. In some cases e.g. the degradation
of most sphingolipids, the water soluble enzymes do not work
properly on membrane-bound lipids and need the support of lipid-
binding proteins [51]. If any of these components is defective, lipids
accumulate, causing secondary accumulation of other lipids and
hydrophobic proteins, and ﬁnally a breakdown of lysosomal digestion.
Then the lysosome can no longer provide the cell with nutrients and
building blocks of macromolecules, and the cell starves.
Lysosomal digestion can also be impaired by certain drugs [52].
Cationic amphiphilic drugs (CADs) can induce the formation of
lamellar bodies, an accumulation of lipids in the lysosome [53]. CADs
are neutral at a pH value of 7 and can penetrate membranes. Once in
the lysosome, CADs are protonated in the acidic environment and
trapped in the lysosome. In their protonated form, they interact with
the negatively charged intra-lysosomal vesicles, displacing enzymes
and eventually the lipid binding proteins. Many lysosomal proteins are
glycoproteins and polycations at acid pH, so that they attach to
negatively charged BMP-containing membranes. With the vesicle on
one side and the glycan part on the other side they are protected from
the degradation by cathepsins. This has been at least demonstrated for
acid sphingomyelinase [54,55] and acid ceramidase [56]. CADs
displace the enzymes, and lead to their premature degradation, and
this induces a lipidosis (Fig. 4). The tricyclic antidepressant desipra-
mine induces rapid intracellular degradation of acid sphingomyeli-
nase and other enzymes, when added to cultured ﬁbroblasts [55].ingomyelinase (ASM) and from glucosylceramide (GlcCer) by the glucosylceramide-β-
terol is transported out of the lysosome by NPC1 and NPC2. The sterol binding site at the
Fig. 5. Structure of ganglioside GM2. Structure of ganglioside GM2.
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feres with the binding of acid sphingomyelinase to the lipid bilayers
and thereby displaces the enzyme from its membrane-bound
substrate. The displacement of the enzyme from the innermembranes
of late endosomes and lysosomes by desipramine might render its
susceptible to proteolytic cleavage by lysosomal proteases [55,57].
Cationic amphiphilic drugs also induce phospholipid accumulation in
lysosomes, by inhibition of lysosomal phospholipase A2 activity [58],
or other mechanisms [52].
1.7. Lysosomal storage diseases
The loss of functional enzymes or activator proteins acting in the
degradation of complex biomolecules leads to the accumulation of
nondegradable enzyme substrates. The corresponding lysosomal
storage diseases are classiﬁed according to the accumulating sub-
stances as sphingolipidoses, mucopolysaccharidoses, mucolipidoses,
glycoprotein and glycogen storage diseases [1]. Insights into the
mechanism of membrane digestion came from the investigation of
GSL catabolism and the metabolic diseases associated with inherited
defects in this pathway. Key features of lysosomal sphingolipid
degradation and principles governing membrane digestion are
discussed in this article.
2. Glycosphingolipid degradation
2.1. Structure and function of glycosphingolipids
Together with glycerophospholipids and cholesterol, sphingolipids
and GSL are membrane components of eukaryotic cell surfaces. They
are characterized by the presence of a sphingoid base within the
hydrophobic part of the molecule. In sphingomyelin and the glyco-
sphingolipids, a phosphorylcholine or a carbohydrate moiety is bound
to the terminal hydroxyl group of ceramide (N-acylsphingosine)
(Fig. 5) [59]. Variations in the type, number and linkage of sugar
residues in the oligosaccharide chain give rise to a wide range of
naturally occurring GSL [60]. Also the lipid moiety can vary in chainFig. 4. Drug induced lipidoses. The molecular view (modiﬁed from [125]). At acidic pH
values (4–5) cationic lysosomal lipid binding proteins (LLBPs) (Saps and GM2-AP) and
exohydrolases bind to the negatively charged surface of BMP containing inner
membranes. To overcome the lipid phase problem, LLBPs bind, extract, and present
membrane-bound lipids to water-soluble exohydrolases for degradation. CADs enter
the lysosome, concentrate in the organelle and interact with inner membranes.length of the fatty acid and sphingoid base and in the degree of
saturation and hydroxylation. GSL form cell-type speciﬁc pattern,
which changes with cell growth, differentiation, viral transformation,
ontogenesis, and oncogenesis [61].
Based on the differential miscibility in vitro and on the differential
solubilities of membrane components in detergent containing solu-
tions at low temperature [62], it is believed that lipids of the plasma
membrane segregate into membrane microdomains. According to this
view, GSL, cholesterol, the phosphosphingolipid sphingomyelin, and
glycosylphosphatidylinositol-anchored proteins form so-called rafts
[63]. So far, the small size and lifetime of these putative objects
prevented their characterization. Single-particle tracking experiments
at high temporal and moderate spatial resolution indicated that single
GPI-anchored proteins are associated with very small (b10 nm)
domains with short lifetimes (b0.1 ms) [64]. Observations of labelled
lipids in the plasma membrane of living cells by the nanoscope
support this view [65]. Antibodies and toxins are able to stain distinct
membrane areas, but single molecule experiments indicate that the
lipid rafts detected by this method are not preexisting, but induced by
this treatment. Also treatment with detergents has been demon-
strated to induce shifts in lipid ratio [66]. Rafts still remain a
hypothesis [67,68].
Glycosphingolipids, sphingomyelin, their lysosomal degradation
products sphingosine and sphingosine-1-phosphate are essential for
development and survival of multicellular organisms [59]. This has
been demonstrated in mice lacking acid ceramidase, which do not
survive the two-cell stage [69]. GSL play a role in cell adhesion
phenomena and in the regulation of membrane proteins [70]. Mice,
that are not able to form ganglioside GM3 show enhanced insulin
receptor phosphorylation and increased insulin sensitivity [71].
Sphingolipid processing is also vital for the barrier function in the
stratum corneum of the human skin, where ceramides of complex
structures occurring at high concentrations, either in free form or
covalently bound to proteins, contribute to the water permeability
barrier [72,73]. GSL of the developing sperm with highly unsaturated
very long chain fatty acids in their ceramide moieties are essential for
male fertility [74].
In addition to disorders caused by inherited alterations of
sphingolipid metabolism, sphingolipids are involved in a variety of
diseases. In infectious diseases, sphingolipids are for example used as
receptors by pathogens and can determine pathogen infection and
host defense [75]. In the immune system, glycosphingolipids play a
role as antigens (AB0-system, Forssman), but can also stimulate the
generation of autoantibodies in postinfectious autoimmune diseases
like Guillain–Barré or Miller–Fisher syndromes [76,77]. In addition,
certain gangliosides can induce a CD1d-restricted natural killer T
(NKT)-cell response [78].
2.2. Biosynthesis of glycosphingolipids
De novo biosynthesis of GSL starts with the formation of ceramide
at the cytoplasmic face of the endoplasmic reticulum (ER) [79]. From
there, ceramide is transferred to the Golgi apparatus by vesicular
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cytoplasmic face of the Golgi apparatus, a glucose residue is added in
β-glycosidic linkage to the 1-position of the ceramide [81,82]. There is
evidence that the lipid-binding protein FAPP2 can mediate the non-
vesicular transport of newly synthesized glucosylceramide (GlcCer),
labelled with a ﬂuorescent dye, to cytosolic surfaces of different
intercellular membranes [83]. Addition of carbohydrate moieties to
GlcCer starts at the luminal face of early compartments of the Golgi
apparatus [84].
The translocation of GlcCer to reach the luminal face of the Golgi
membranes for the biosynthesis of complex glycosphingolipids is a
controversial issue, since some results have been obtained with
ﬂuorescent labelled GlcCer, which behaves not always like the
endogenous one. Fluorescent-labelled GlcCer can eventually be
translocated by a multidrug transporter, to reach the luminal face of
the organelle [85]. In skin cells, the lipid transporter ABCA12 has been
implicated to be involved in GlcCer translocation [86–88]. Halter et al.
found, however, that tritium-labelled GlcCer – free of any ﬂuorescent
tag – destined for glycolipid synthesis follows a different pathway and
transports back to the ER via FAPP2 [89], where it can translocate to
the luminal surface of the membranes. From there the newly
synthesized GlcCer can reach the luminal face of Golgi membranes,
where it becomes substrate of lactosylceramide synthase [89]. This ﬁts
to the view of the Golgi apparatus as a continuous two-dimensional
gradient of proteins and lipids in a structure of interconnected
cisternae that may be progressing [90].
On the luminal side of the Golgi apparatus, membrane-resident
glycosyltransferases elongate the carbohydrate chain by the stepwise
addition of single carbohydrate residues. Due to the topology of the
biosynthesis, the oligosaccharide moieties of most GSL face the
extracytoplasmic side of the plasma membrane, or the lumen of
cellular organelles respectively. The limited speciﬁcity of some of the
glycosyltransferases gives rise to the complex patterns of gangliosides
on the cell surface within a combinatorial biosynthetic pathway
[60,91]. After their biosynthesis, GSL reach the plasma membrane
through vesicular exocytotic membrane ﬂow.
2.3. Lysosomal glycosphingolipid degradation and sphingolipid activator
proteins
Areas of the plasma membrane bud into clathrin-coated pits, non-
clathrincoated pits, caveolae or others, are internalized, if necessary
uncoated, and fuse with early endosomes [92]. Here, parts of the
endosomal membrane enriched in components derived from the
plasma membrane invaginate and bud into the endosomal lumen.
Accordingly, GSL derived from the plasma membrane reach the
lysosome on the lysosolic side of small intra-lysosomal vesicles and
other membrane structures, these are the platforms for sphingolipid
and membrane degradation [6,51]. Degradation of sphingolipids
derived from the cell surface that become part of the limiting
membrane of endosomes and lysosomes, however is prevented by
the thick glycocalyx, which protects the membrane from the attack by
degrading enzymes. The lysosomal degradation of GSL is a sequential
pathway that starts with the stepwise release of monosaccharide units
from the nonreducing end of the oligosaccharide chain, catalyzed by
exohydrolases with acidic pH-optima (Fig. 6). The substrates of the
water soluble hydrolases are embedded in intraendosomal and intra-
lysosomal membranes [93–95], whereas the soluble enzymes are
dissolved in the lumen of the lysosome. In vivo, GSLwith less than four
sugar residues [96] are only degraded in the presence of sphingolipid
activator proteins (SAPs). In vitro, these SAPs can often be replaced by
detergents. SAPs mediate the interaction between the membrane
bound lipid substrate and the water-soluble enzyme, or activate the
enzyme directly. The SAPs comprise ﬁve small non-enzymatic
glycoproteins, encoded by two genes. One gene codes for the precursor
of the GM2 activator protein (GM2-AP) [97]. The second gene codes forprosaposin, which is proteolytically processed to four highly homo-
logous proteins, the Saps or saposins A–D [98]. These ﬁve activator
proteins (GM2-AP and the Saps A–D) act on the surface of the intra-
endosomal/intra-lysosomal membrane vesicles, making the lipid
substrate accessible to the degrading enzyme. The GM2-AP acts as an
essential cofactor in the in vivo degradation of ganglioside GM2 by β-
hexosaminidase A [99]. Inherited deﬁciencyof theGM2-AP leads to the
AB variant of GM2 gangliosidosis. The GM2-AP is a glycoprotein with
17.6 kDa in its deglycosylated form, it bears a N-glycosidically bound
oligosaccharide chain and contains four disulﬁde bridges [100,101].
The X-ray crystallographic structure of non-glycosylated GM2-AP,
expressed in Escherichia coli allowed an understanding of the role of
this protein on membrane degradation [102–104]. The GM2-AP
contains a hydrophobic cavity that harbors the ceramide moiety of
ganglioside GM2. Extraction of the GSL out of the intra-lysosomal
membrane is followed by a conformational change of the lipid loaded
activator, which increases the water solubility of the complex [105]
(Fig. 7). The major determinant for the interaction with the enzyme
that degrades GM2 has been identiﬁed as a single short α-helix of
GM2-AP [106]. The GM2-AP can be regarded as a weak detergent with
high selectivity that inserts into the bilayer of intra-lysosomal lipid
vesicles and lifts gangliosides like GM2 andGM1 and other lipids out of
themembrane, so that they become accessible for the active site of the
degrading enzyme [96]. As a “liftase” [5] the GM2-AP forms
stoichiometric, water-soluble glycolipid-protein complexes that are
physiological Michaelis–Menten substrates of β-Hexosaminidase A
[99,106]. Physico-chemicalmeasurementswith lipidmonolayers show
that the GM2-AP can insert only if the lateral pressure is below 15–
25 mN m−1 [107]. It can be assumed that the GM2-AP cannot insert
into the lysosomal perimeter membrane due to its higher `lateral
pressure´. The `lateral pressure´ of biologicalmembranes correlates to a
range between 30 and 35 mN m−1 [108]. Although no data on intra-
lysosomal vesicles are available, it can be assumed that their `lateral
pressure´. is quite low due to their low cholesterol and their high BMP
content, enabling the GM2-AP to insert into the intra-lysosomal
vesicles, but not into the perimeter membrane.
The Saps A–D are four acidic, not enzymatically active, heat-stable
and protease-resistant glycoproteins of about 8–11 kDa [51]. They are
members of the saposin-like protein family (SAPLIPs), which
comprises proteins and protein domains of several species and
different function, all sharing a lipid-binding and membrane perturb-
ing properties [109]. The ﬁrst SAPLIP for which structure determina-
tion has been successful, was the elucidation of NK-lysin by nuclear
magnetic resonance spectroscopy [110]. Up to now, several other
SAPLIP structures have been determined, among them the solution
structure of Sap-C [111] and the X-ray crystallographic structure of
unglycosylated human recombinant Sap-A [112], Sap-C [113], Sap-B
[113], and Sap-D [114]. The proteins show high structural similarity.
They are characterized by the presence of three intradomain disulﬁde
linkages and several hydrophobic residues that form a common
structural framework. Despite their high degree of homology, the Saps
differ in speciﬁcity. The absence of different Saps leads to different
sphingolipidoses. Although all Saps are able to mobilize lipids from
membranes, this indicates that additional Sap-speciﬁc properties are
required. The physiological degradation of sphingomyelin does not
require the presence of an activator protein, since acid sphingomye-
linase contains a protein domain with homology to the Saps [57].
The in vivo-degradation of galactosylceramide by galactosylcer-
amide-β-galactosidase requires in vivo the presence of Sap-A. Mice
carrying a mutation in the Sap-A domain of the Sap-precursor and
therefore lack mature Sap-A accumulate galactosylceramide and
develop a late-onset form of Krabbe disease [115]. Glycosylated Sap-
A mobilizes lipids from low cholesterol and high BMP containing
membranes [116].
Sap-B was the ﬁrst activator protein to be identiﬁed: originally it
was called sulphatide activator protein [117]. It is required for the in
Fig. 6. Lysosomal degradation of selected sphingolipids [59]. The eponyms of individual inherited diseases are given. Activator proteins required for the respective degradation step in
vivo are indicated. AB variant: AB variant of GM2 gangliosidosis (deﬁciency of GM2-AP).
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ceramide and digalactosylceramide by α-galactosidase A. The inher-
ited defect of Sap-B leads to an atypical form of metachromatic
leukodystrophy [118,119]. The disease is characterized by accumula-
tion of sulfatides, digalactosylceramide, and globotriaosylceramide.
The crystal structure of Sap-B shows a shell-like homodimer that
encloses a large hydrophobic cavity [113]. The monomers are
composed of four amphipathic α-helices arranged in a long hairpinFig. 7. Model of GM2-AP-stimulated hydrolysis of ganglioside GM2 by human β-hexosaminida
L163) surface loops and a single short helix. The most ﬂexible of the loops (V153–L163) contro
According to thismodel, theGM2-AP lifts or extracts gangliosideGM2 fromthemembraneund f
of GM2. Then the product may return to the membrane, but this has not been demonstrated.that is bent into a V-shape. As in the case of the GM2-AP, there are two
different conformations of the Sap-B dimers, and a similar mechanism
for its action has been proposed: the open conformation should
interact directly with the membrane, promote a reorganization of the
lipid alkyl chains, and extract the lipid substrate accompanied by a
change to the closed conformation, so that the substrate can be
exposed to the enzyme in a water-soluble activator lipid complex
[120]. This is consistent with the observation that, after initial binding,se A [105]. The glycolipid binding site is lined by two hydrophobic (V90–W94 and V153–
ls the entrance to the hydrophobic cavity allowing both, an open and closed conformation.
orms a complexwith theβ-hexosaminidase A. Thenext stepof theprocess is thehydrolysis
GM2-AP, GM2-activator protein; Hex A, β-hexosaminidase A.
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lizes lipids from it [121].
Sap-C is required for the lysosomal degradation of glucosylcer-
amide by glucosylceramide-β-glucosidase. The 20 kDa homodimeric
protein was ﬁrst isolated from the spleens of patients with Gaucher
disease [122]. In contrast to Sap-B, Sap-C binds not only to lipids and
membranes, but also interacts with glucosylceramide-β-glucosidase
and stimulates the enzyme directly [123,124]. The β-glucosidase is a
water soluble lysosomal enzyme that can associate to membranes.
Sap-C also supports the interaction of the enzyme with the substrate
embedded in vesicles containing anionic phospholipids. In addition,
Sap-C is able to destabilize these vesicles [125]. Binding of Sap-C to
phospholipid vesicles is a pH-controlled, reversible process [126]. The
deﬁciency of Sap-C leads to an abnormal juvenile form of Gaucher
disease and an accumulation of glucosylceramide [127,128]. Feeding of
puriﬁed Sap-C to patients ﬁbroblasts reduces the level of glucosylcer-
amide storage, whereas Sap-A, -B and -D were not effective [129].
Additionally, Sap-C renders glucosylceramide-β-glucosidase more
protease-resistant inside the cell [130]. The solution structure of
Sap-C [111] consists of ﬁve tightly packed α-helices that form half of a
sphere. All charged amino acids are solvent-exposed, whereas the
hydrophobic residues are contained within the protein core. Sap-C
locally alters regions of lipid bilayer for subsequent attack by acid β-
glucosidase [131].
Sap-D stimulates lysosomal ceramide degradation by acid cerami-
dase in cultured cells [129] and in vitro [132]. The detailed physiological
function and mode of action of Sap-D is unclear. It is able to bind to
vesicles containingnegatively charged lipids and to solubilize themat an
appropriate pH [133]. Sap-D-deﬁcient mice accumulate ceramides with
hydroxylated fatty acids mainly in the brain and in the kidney [134]. In
addition to their function as enzyme cofactors, SAPs play an impor-
tant role in the presentation of lipid and glycolipid antigens. CD1
immunoreceptors present lipid antigens to T cells. Therefore, the lipid
antigens have to be removed from the membranes in which they are
embedded to allow loading on CD1 molecules.
Antigen presentation by human CD1b [135], and human [136], and
mouse CD1d [137] have been studied. Human CD1b especially
requires Sap-C to present different types of glycolipid antigens. In
vitro, all saposins can exchange phosphatidylserine bound to murine
CD1d against glycosphingolipids, but with different activity.
3. Perspective
Cellular membranes are highly dynamic structures. Eukaryotic
cells maintain their morphology, endomembrane homeostasis, and
composition of the intracellular organelles despite continuous inward
and outward membrane ﬂow. The role of endosomes and lysosomes
for lipid homeostasis can be illustrated by one example: Impairment
of cholesterol-efﬂux out of the lysosomes in NPC1-diseases causes not
only lysosomal accumulation of cholesterol in neuronal cell bodies,
but cholesterol-depletion in the axons of neuronal cells, inhibiting
axonal growth [138]. The molecular mechanisms underlying these
processes are not completely understood [139]. Control of membrane
homeostasis remains an open ﬁeld.
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